DE2950977C2 - - Google Patents
Info
- Publication number
- DE2950977C2 DE2950977C2 DE2950977A DE2950977A DE2950977C2 DE 2950977 C2 DE2950977 C2 DE 2950977C2 DE 2950977 A DE2950977 A DE 2950977A DE 2950977 A DE2950977 A DE 2950977A DE 2950977 C2 DE2950977 C2 DE 2950977C2
- Authority
- DE
- Germany
- Prior art keywords
- granules
- preparation form
- form according
- crushed
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008187 granular material Substances 0.000 claims description 68
- 239000003814 drug Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 47
- 239000004480 active ingredient Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 238000007906 compression Methods 0.000 claims description 16
- 230000006835 compression Effects 0.000 claims description 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 9
- 235000005985 organic acids Nutrition 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001800 Shellac Polymers 0.000 claims description 5
- 238000002483 medication Methods 0.000 claims description 5
- 239000004208 shellac Substances 0.000 claims description 5
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 5
- 229940113147 shellac Drugs 0.000 claims description 5
- 235000013874 shellac Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical class OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- 229930182555 Penicillin Natural products 0.000 description 10
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 10
- 229960002768 dipyridamole Drugs 0.000 description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 229960002726 vincamine Drugs 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000013065 commercial product Substances 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 229940099112 cornstarch Drugs 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 229930195708 Penicillin V Natural products 0.000 description 3
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- -1 glentamicid Chemical compound 0.000 description 3
- 229940056367 penicillin v Drugs 0.000 description 3
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 3
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 description 2
- YEYCQJVCAMFWCO-UHFFFAOYSA-N 3beta-cholesteryl formate Natural products C1C=C2CC(OC=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YEYCQJVCAMFWCO-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 1
- 229950001647 clometacin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
- 229960001650 glafenine Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7836084A FR2444460A1 (fr) | 1978-12-22 | 1978-12-22 | Nouvelle forme galenique a usage oral, et son procede de preparation |
| FR7908181A FR2452923A2 (fr) | 1979-04-02 | 1979-04-02 | Nouvelle forme galenique d'administration de medicaments par voie orale, a liberation programmee |
| FR7908180A FR2452922A2 (fr) | 1979-04-02 | 1979-04-02 | Nouvelle forme galenique d'administration de medicaments par voie orale, a liberation programmee |
| FR7930041A FR2470600A2 (fr) | 1979-12-07 | 1979-12-07 | Nouvelle forme galenique d'administration de medicaments par voie orale, a liberation programmee |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2950977A1 DE2950977A1 (de) | 1980-07-10 |
| DE2950977C2 true DE2950977C2 (instruction) | 1987-11-05 |
Family
ID=27446389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792950977 Granted DE2950977A1 (de) | 1978-12-22 | 1979-12-18 | Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US4609542A (instruction) |
| AR (1) | AR229346A1 (instruction) |
| AT (1) | AT376567B (instruction) |
| CH (1) | CH647676A5 (instruction) |
| DE (1) | DE2950977A1 (instruction) |
| ES (1) | ES487151A1 (instruction) |
| GB (1) | GB2039737B (instruction) |
| IE (1) | IE48715B1 (instruction) |
| IT (1) | IT1164548B (instruction) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH647676A5 (fr) * | 1978-12-22 | 1985-02-15 | Donald E Panoz | Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation. |
| FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3127237A1 (de) * | 1981-07-10 | 1983-01-20 | Hoechst Ag, 6000 Frankfurt | Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung |
| EP0094117A3 (en) * | 1982-05-06 | 1984-08-01 | The Procter & Gamble Company | Therapeutic granules |
| EP0094123A3 (en) * | 1982-05-06 | 1984-07-25 | THE PROCTER & GAMBLE COMPANY | Therapeutic granules |
| EP0094116A3 (en) * | 1982-05-06 | 1984-08-01 | The Procter & Gamble Company | Therapeutic granules |
| PH18946A (en) * | 1983-04-21 | 1985-11-14 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
| IE56459B1 (en) * | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
| IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
| US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| DE3572440D1 (en) * | 1984-06-19 | 1989-09-28 | Basf Ag | Gastro-resistant cylindrical pancreatine-microtablets |
| US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
| US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| IT1204839B (it) * | 1986-03-14 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti vinburnina e loro procedimento di preparazione |
| NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5122384A (en) * | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
| DK0585355T3 (da) * | 1991-05-20 | 1995-06-06 | Tanabe Seiyaku Co | Flerlagspræparat med reguleret frigivelse |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5429822A (en) * | 1992-03-13 | 1995-07-04 | Cambridge Scientific, Inc. | Biodegradable bursting release system |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| US5310961A (en) * | 1993-07-02 | 1994-05-10 | Affinity Biotech, Inc. | Neomorphic ibuprofen |
| US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
| FR2733423B1 (fr) * | 1995-04-26 | 1997-06-20 | Virbac Lab | Compositions pulverulentes et solubles dans l'eau et leurs applications |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| US5721229A (en) * | 1995-12-26 | 1998-02-24 | Veterinary Pharmacy Corporation | Soluble forms of cephalosporins and treatment of animals |
| US6312724B1 (en) | 1997-04-04 | 2001-11-06 | Isa Odidi | Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof |
| US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| US6225304B1 (en) * | 1999-02-17 | 2001-05-01 | Pharmaceutical Solutions, Inc. | Soluble forms of amoxicillin and treatment of animals |
| US6596307B1 (en) * | 1999-06-15 | 2003-07-22 | Eli Lilly And Company | Process for preparing pharmaceutical bulk material having uniform dissolution |
| JP3893058B2 (ja) * | 1999-09-30 | 2007-03-14 | ペンウェスト ファーマシューティカルズ カンパニー | 高度に可溶性の薬物のための徐放性マトリックス系 |
| CA2389235C (en) | 1999-10-29 | 2007-07-17 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR100968128B1 (ko) | 2000-10-30 | 2010-07-06 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US20040029959A1 (en) * | 2002-08-08 | 2004-02-12 | John Devane | Isosorbide mononitrate compositions and methods of their use |
| US8865197B2 (en) * | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
| KR101413613B1 (ko) * | 2006-01-27 | 2014-07-10 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 |
| CA2640382C (en) * | 2006-01-27 | 2015-12-29 | Eurand, Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
| EP1820506B1 (en) * | 2006-02-09 | 2008-03-26 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
| EP2068840A2 (en) * | 2006-07-21 | 2009-06-17 | LAB International SRL | Hydrophobic abuse deterrent delivery system |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| MX2011002515A (es) * | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita. |
| WO2010036975A2 (en) * | 2008-09-25 | 2010-04-01 | Teva Pharmaceutical Industries Ltd. | Dipyridamole and acetylsalicylic acid formulations and process for preparing same |
| CN102638978A (zh) * | 2009-06-25 | 2012-08-15 | 波曾公司 | 用于治疗需要阿司匹林治疗之患者的方法 |
| EA201290026A1 (ru) | 2009-06-25 | 2012-07-30 | Астразенека Аб | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH283585A (de) * | 1950-03-15 | 1952-06-15 | Hoffmann La Roche | Zur Herstellung von Tablettenüberzügen geeignetes Gemisch. |
| US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
| US2996431A (en) * | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US3044938A (en) * | 1955-07-01 | 1962-07-17 | Sandoz Chemical Works Inc | Sustained action pharmaceutical tablets |
| GB785262A (en) * | 1955-09-23 | 1957-10-23 | Smith Kline & French Internat | Improvements in or relating to hypotensive and sedative preparations |
| US2809917A (en) * | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical tablets |
| US2809918A (en) * | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| US2853420A (en) * | 1956-01-25 | 1958-09-23 | Lowey Hans | Ethyl cellulose coatings for shaped medicinal preparations |
| US2897122A (en) * | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
| GB831907A (en) * | 1957-09-12 | 1960-04-06 | Organon Labor Ltd | Suspensions of drugs destined for injection and process for the preparation thereof |
| US2918411A (en) * | 1957-11-01 | 1959-12-22 | Olin Mathieson | Pharmaceutical preparations |
| NL109170C (instruction) * | 1958-02-03 | |||
| DE1248863B (instruction) * | 1959-01-30 | |||
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US2993837A (en) * | 1959-07-13 | 1961-07-25 | Frosst & Co Charles E | Enteric coated tablets |
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
| NL122039C (instruction) * | 1960-10-20 | |||
| US3102845A (en) * | 1960-11-18 | 1963-09-03 | Mcneilab Inc | Pharmaceutical tablet |
| US3166476A (en) * | 1961-09-01 | 1965-01-19 | Lowey Hans | Powder based tablets |
| US3115441A (en) * | 1962-06-06 | 1963-12-24 | Victor M Hermelin | Timed release pharmaceutical preparations and method of making the same |
| FR1347413A (fr) * | 1963-01-29 | 1963-12-27 | Italnysco S P A | Sphérules ou globules à action étalée et procédé pour leur préparation |
| US3325365A (en) * | 1963-04-02 | 1967-06-13 | Ciba Geigy Corp | Enteric composition for tablet compression coating |
| NL297631A (instruction) * | 1963-06-03 | |||
| GB1204580A (en) * | 1968-10-05 | 1970-09-09 | Aspro Nicholas Ltd | Pharmaceutical dosage forms |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US3725470A (en) * | 1969-05-14 | 1973-04-03 | Hoffmann La Roche | Amino acid derivatives |
| CH521313A (de) * | 1969-05-14 | 1972-04-15 | Hoffmann La Roche | Verfahren zur Herstellung von Phenylalaminderivaten |
| US3629393A (en) * | 1969-09-11 | 1971-12-21 | Nikken Chemicals Co Ltd | Release-sustaining-tablet |
| DE2010116A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
| GB1359643A (en) * | 1970-09-28 | 1974-07-10 | Controlled Medications | Controlled release medicament |
| US4025613A (en) * | 1971-07-19 | 1977-05-24 | Richard G. Powers | Timed-release aspirin |
| US3828106A (en) * | 1972-01-03 | 1974-08-06 | Biolog Concepts Inc | Novel oral pharmaceutical dosage form |
| GB1443923A (en) * | 1972-05-02 | 1976-07-28 | Shepard M | Sustained release compositions |
| US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
| US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
| GB1367608A (en) * | 1973-03-09 | 1974-09-18 | Biolog Concepts Inc | Oral pharmaceutical dosage form |
| US3954959A (en) * | 1973-03-28 | 1976-05-04 | A/S Alfred Benzon | Oral drug preparations |
| GB1422176A (en) * | 1973-05-05 | 1976-01-21 | Beecham Group Ltd | Pharmaceutical tablets |
| US4113816A (en) * | 1973-07-12 | 1978-09-12 | Choay S.A. | Process for the manufacture of layered tablets incorporating controlled-release microcapsules |
| US3961004A (en) * | 1974-04-11 | 1976-06-01 | Auburn Research Foundation | Method of tabletting using gluconolactone as the direct compression diluent |
| GB1551954A (en) * | 1975-05-28 | 1979-09-05 | Hoffmann La Roche | Standardization of a physiochemical parameter of a batch of formulation in tabletted form |
| US4016744A (en) * | 1975-05-28 | 1977-04-12 | Hoffmann-La Roche Inc. | Applied instrumentation providing tabletting compression force |
| FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
| SE418247B (sv) * | 1975-11-17 | 1981-05-18 | Haessle Ab | Sett att framstella kroppar med reglerad frigoring av en aktiv komponent |
| GB1561301A (en) * | 1976-01-02 | 1980-02-20 | Beecham Group Ltd | Orally administrable pharmaceutical composition |
| US4137300A (en) * | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
| HU174057B (hu) * | 1976-09-17 | 1979-10-28 | Richter Gedeon Vegyeszet | Sostav dlja pokrytij obespechivajuhhij uregulirovannuju otdachy aktivnogo vehhestva biologicheski aktivnykh preparatov i sposob poluchenija takikh preparatov s uregulirovannoj otdachej aktivnogo vehhestva |
| FR2368272A1 (fr) * | 1976-10-20 | 1978-05-19 | Theramex | Compositions therapeutiques solides pour combattre l'agregation plaquettaire |
| LU77353A1 (instruction) * | 1977-05-16 | 1979-01-19 | ||
| CH647676A5 (fr) * | 1978-12-22 | 1985-02-15 | Donald E Panoz | Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation. |
| US4321253A (en) * | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
-
1979
- 1979-12-18 CH CH11224/79A patent/CH647676A5/fr not_active IP Right Cessation
- 1979-12-18 IE IE2452/79A patent/IE48715B1/en not_active IP Right Cessation
- 1979-12-18 DE DE19792950977 patent/DE2950977A1/de active Granted
- 1979-12-19 GB GB7943731A patent/GB2039737B/en not_active Expired
- 1979-12-20 ES ES487151A patent/ES487151A1/es not_active Expired
- 1979-12-21 AR AR279420A patent/AR229346A1/es active
- 1979-12-21 IT IT28301/79A patent/IT1164548B/it active
- 1979-12-21 AT AT0808179A patent/AT376567B/de not_active IP Right Cessation
-
1985
- 1985-07-01 US US06/750,980 patent/US4609542A/en not_active Expired - Lifetime
- 1985-07-01 US US06/750,934 patent/US4726951A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4726951A (en) | 1988-02-23 |
| US4609542A (en) | 1986-09-02 |
| IT1164548B (it) | 1987-04-15 |
| AT376567B (de) | 1984-12-10 |
| ATA808179A (de) | 1984-05-15 |
| DE2950977A1 (de) | 1980-07-10 |
| GB2039737B (en) | 1983-07-20 |
| CH647676A5 (fr) | 1985-02-15 |
| IE48715B1 (en) | 1985-05-01 |
| IE792452L (en) | 1980-06-22 |
| AR229346A1 (es) | 1983-07-29 |
| GB2039737A (en) | 1980-08-20 |
| ES487151A1 (es) | 1980-09-16 |
| IT7928301A0 (it) | 1979-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2950977C2 (instruction) | ||
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| DE3050131C2 (instruction) | ||
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| DE1492107C3 (de) | Verfahren zur Herstellung einer Acetylsalicylsauretablette | |
| AT396329B (de) | Pharmazeutische granulate und verfahren zu ihrer herstellung | |
| EP0108898B1 (de) | Neue orale Mopidamolformen | |
| DE3872739T2 (de) | Arzneimittel mit langsamer freisetzung. | |
| DE2224534B2 (de) | Pharmazeutisches praeparat mit langsamer wirkstoffabgabe | |
| DD216163A5 (de) | Verfahren zur herstellung eines oral verabfolgbaren cefaclor-praeparates mit verzoegerter wirkstoffabgabe | |
| EP0009688B1 (de) | Medikiertes Tierfutter auf Basis Lebermehl und Verfahren zu seiner Herstellung | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE2323686A1 (de) | Arzneimittelzubereitungsform mit langzeitwirkung und verfahren zu ihrer herstellung | |
| EP0472502A1 (de) | Verfahren zur Herstellung von Pellets | |
| DE2813146A1 (de) | Tablettieren von mikrokapseln | |
| EP0386440A1 (de) | Arzneimittel mit kontrollierter Wirkstoffabgabe | |
| EP0469328B1 (de) | Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen | |
| EP0052076A1 (de) | Schnellzerfallende Arzneimittel-Presslinge | |
| EP0146863A2 (de) | Orale retardierte Acetylsalicylsäureformulierungen | |
| DE60220436T2 (de) | Microkügelchen mit einem pleuromutilin-derivat | |
| DE69816124T2 (de) | Pharmazeutische zusammensetzungen enthaltend zafirlukast | |
| DD258992A1 (de) | Verfahren zum gleichzeitigen trocknen und granulieren von extaktstoffen aus enteiweissten kaelberblut | |
| DE2630326A1 (de) | Pharmazeutisches praeparat zur behandlung der osteoporose und verfahren zu seiner herstellung | |
| DE3810350A1 (de) | Dhp-retard-zubereitung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: ELAN CORP. P.L.C., ATHLONE, COUNTY WESTMEATH, IE |
|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |